Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

d Haemophilus influenzae and a once-a-day option at a significantly lower dose than linezolid. Additionally, these results further validate Rib-X's proprietary discovery and development approach which led to the identification of this compound as well as multiple other novel compounds in various classes which are able to circumvent bacterial resistance mechanisms."

Study Results

The poster, entitled "A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)," reported that clinical cure rates with a 95% confidence interval in clinically evaluable patients were 97.4% for patients treated with radezolid at a dosage of 450 mg once a day (38/39); 94.4% for patients treated with radezolid 450 mg twice a day (36/39); and 97.4% for patients treated with linezolid 600 mg twice a day (37/38).

Clinical cure rates among clinically evaluable patients with confirmed MRSA infections with a 95% confidence interval were 100% and 92.9% for patients treated with radezolid once a day (8/8) and twice a day (13/14), respectively, and 93.3% for patients treated with linezolid 600 mg twice a day (14/15). In microbiologically evaluable patients, eradication was achieved in 100% of the group treated with radezolid at 450 mg once a day (20/20), and 87.5% in the group receiving radezolid 450 mg twice daily (21/24), versus 91.3% in the group receiving linezolid 600 mg twice daily (21/23).

uSSSI Phase 2 Trial Design

This Phase 2 trial, which enrolled 150 patients, was a multicenter, randomized, open-label, comparative study conducted at 19 clinical centers across the U.S. to evaluate the safety and efficacy of radezolid versus linezolid in the outpatient treatment of adult patients with uncomplicated skin and skin structure infections (uSSSI). The study assessed the efficacy of a 450mg dose of radezolid given orally, either once daily or twice daily for five to ten days compared to a 6
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur ... is still strongly maintaining her firm’s success in the hair care and distribution ... upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, as ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... ranked a top-five hospital by U.S. News & World Report, to provide breaking ... , Editorial and marketing groups within OncLive, which provides oncologists resources and ...
(Date:9/1/2015)... ... 01, 2015 , ... The Jerry Segal Classic to benefit the patients of ... Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized ... and services designed to support patients and their families during their time at Magee ...
(Date:9/1/2015)... , ... September 01, 2015 , ... With former IBMers ... and Math) disciplines since its inception more than 35 years ago. A pilot program ... and their teachers - and, not just those intent on pursuing careers in these ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of version 5.2 of the FirstSpirit Content Management System with ... initiative. With the new version of FirstSpirit, companies will be well on their ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... By Amanda Gardner HealthDay Reporter , TUESDAY, Jan. ... moved to rescind approval of the drug Avastin to treat ... anti-cancer medication ups the odds of congestive heart failure in ... the Journal of Clinical Oncology , included almost 4,000 ...
... Researchers have produced a lasting anti-cocaine immunity in mice by ... cold virus with a particle that mimics cocaine. , ... the online edition of Molecular Therapy and funded by ... strategy might be the first to offer cocaine addicts a fairly ...
... -- Elderly people who lose their teeth may be at ... study included more than 4,000 Japanese participants, 65 and older, ... with participants who still had many of their natural teeth, ... to have experienced some memory loss or have early-stage Alzheimer,s ...
... cortical nerve cells or neurons reside in the brain,s gray ... matter, but some people with schizophrenia have a higher number ... arise in schizophrenia as a consequence of both genetic and ... has now been studied in detail in a paper by ...
... , New Rochelle, NY, January 4, 2011Lowering the body ... severe brain injury may reduce neurologic complications and improve ... injury (TBI) has been demonstrated in national studies. According ... field, when and how it is administered should depend ...
... TUCSON, Ariz. (January 4, 2011) -- Cumbersome glaucoma tests ... history thanks to a home test developed by an ... hand-held instrument involving a system of micro-force sensors, specially ... by researchers at the UA College of Engineering. The ...
Cached Medicine News:Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Vaccine blocks cocaine high in mice 2Health News:Vaccine blocks cocaine high in mice 3Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Optimizing patient outcomes after therapeutic hypothermia for traumatic brain injury 2Health News:New glaucoma test allows earlier, more accurate detection 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: